Tumour markers in epithelial ovarian cancer;Tumormarkører ved epitelial ovariecancer

Ugeskrift for Laeger

Volumn 171, Issue 48, 2009, Pages

  Sparholt, Morten H ^a   Høgdall, Estrid ^a   Høgdall, Claus K ^a   Marie, Juliane ^a  

^a NONE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; FEMALE; GENETIC PREDISPOSITION; HUMAN; IMMUNOLOGY; MASS SCREENING; OVARY TUMOR; PERSONALIZED MEDICINE; REVIEW; SENSITIVITY AND SPECIFICITY;

CA-125 ANTIGEN; CHEMOTHERAPY, ADJUVANT; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIVIDUALIZED MEDICINE; MASS SCREENING; OVARIAN NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 77954916315     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Cliby W, Dowdy S, Feitoza SS et al. Diaphragm resection for ovarian cancer: Technique and short-term complications. Gynecol Oncol 2004;94:655-60.
2. Høgdall EVS, Christensen L, Kjaer SK et al. Distribution of Her-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma. Cancer 2003;98:66-73.
3. Kjærbye-Thygesen A, Huusom LD, Frederiksen K et al. Trends in the incidence and mortality og ovarian camcer in Denmark 1978-2002. Comparison with other Nordic countries. Acta Obstet Scand 2005;84:1006-12.
4. Høgdall EVS, Christensen L, Kjaer SK et al. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From the Danish "MALOVA" Ovarian Cancer Study. Gynecol Oncol 2007;104;508-15.
5. Blaakaer J, Engelholm SA, Grove A et al. Epithelial ovariecancer. Rekommandationer for diagnostik og behandling i Danmark. Dansk Gynækologisk Cancer, 2003. http://dgc.eu.com/ (20. oktober 2008).
6. Olsen J. Screening - hvilken dokumentation må man forlange? Ugeskr Læger 2002;164:148-52.
7. Menon U. Ovarian cancer screening. CMAJ Oncology 2004;171:4.
8. Rosenthal A, Menon U, Jacobs J. Screening for ovarian cancer. Clin Obstet Gyn 2006;49:433-47.
9. Rapkiewicz AM, Espina V, Petricoin III EF et al. Biomarkers of ovarian tumors. Eur J Cancer 2004;40:2604-12.
10. Jacobs IJ, Skates SJ, MacDonald N et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999;353:1207-10.
11. Clemmensen I, Petersen LC, Kluft C. Purification and characterization of a novel, oligomeric, plasminogen kringle 4 binding protein from human plasma: tetranectin. Eur J Biochem 1986;156:327-33.
12. Høgdall CK. Human tetranectin: methodological and clinical studies. APMS Suppl 1998;86:1-31.
13. Høgdall CK, Mogensen O, Tabor A et al. The role of serum tetranectin, CA125, and a combined index as tumor markers in women with pelvic tumors. Gynecol Oncol 1995;56:22-8.
14. Diamandis EP. Mass spectofotometry as a diagnostic and a cancer biomarker discovery tool. Opportunities and potential limitations. Mol Cell Proteomics 2004;3:367-78.
15. Dehn E, Hogdall EVS, Johansen JS et al. YKL-40, as a prognostic tumor marker in recurrent ovarian cancer. Proc Am Soc Clin Oncol 2003;82:287-93.
16. Cannistra SA. Cancer of the ovary. New Engl J Medicine 2004;351:2519-29.
17. Fields MM, Chevlen E. Ovarian cancer screening: a look of evidence. Clin J Oncol Nurs 2006;10:77-81.
18. Bosse K, Rhiem K, Wappenschmidt B et al. Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial predisposition: a prospective cohort study. Gynecol Oncol 2006;103:1077-82.
19. Andersen ES, Knudsen Aa, Rix P et al. Risk and malignancy index in the preoperative evaluation of patients with adnexal masses. Gynecol Oncol 2003;90:109-12.
20. Eisenkop SM, Spirtos NM, Montag TW et al. The impact of subspeciality training on the management of advanced ovarian cancer. Gynecol Oncol 1992;47:203-9.
21. Andersen ES, Knudsen Aa, Tetsche M et al. The results of treatment of epithelial ovarian cancer after centralisation of primary surgery. Results from North Jutland, Denmark. Gynecol Oncol 2005;99:552-6.
22. Nishizuka S, Chen S-T, Gwadry FG et al. Diagnostic markers that distinguish colon and ovarian adenocarcinomas: Identification by genomic, proteomic, and tissue array profiling. Cancer Research 2003;63:5243-50.
23. Nielsen HJ, Christensen IJ, Brünner NÅ. Serologiske markører ved kolorektal cancer. Ugeskr Læger 2005;167:4163-7.
24. Berek JS, Taylor PT, Gordon A et al. Randomized, placebo-controlled study of Oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol 2004;22:3507-16.
25. Bookman MA, Darcy KM, Clarke-Pearson D et al. Evaluation of monoclonal humanized anti-HER2 antibody, Trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overekspression of HER2: A phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003;21:283-90.
26. Guastalla JP, Allouache D, Combe M et al. HER2 overexpression and amplification in advanced ovarian cancer (AOC): Treatment with trastuzumab - a GINECO study. J Clin Oncol 2007;25:5559.